phone

FOOT & ANKLE APPLICATIONS

Whether you are addressing damaged tissue in articular cartilage, Achilles tendon or Plantar Fascia attachment points, or surrounding soft tissue; consider Wharton’s jelly for Connective Tissue Supplementation to repair or replace the damaged tissue with new healthy connective tissue.

Contact Us
arrow
foot with emphasis on ankle

Foot and ankle issues don’t discriminate, anyone can experience tissue damage and loss of mobility.

Regenative Labs’ trademarked products and approach goes beyond masking the pain. We want to address the root cause and provide hope for those experiencing issues with foot or ankle tissues. An often-overlooked area for professional athletes—as well as amateur sports enthusiasts— is the importance of the health of connective tissue.

Wharton’s jelly allografts are intended for homologous use only and consist of donated human umbilical cord tissue that has been disassociated, suspended in saline, and cryopreserved.

Their main function is to provide cushioning and structural support and to replace missing or damaged tissue in the patient, applied directly to the defect, or injured area, in joints and soft tissues. The allografts are applied via syringe and are typically used in ligament, muscle, or cartilage tears.

We’ve all read countless stories about a promising or successful athlete who is unable to reach their full potential because they get an injury that either sets them back from their peak training conditions or is career ending. And as you know, it doesn’t end there. Foot and ankle tissue issues can affect anyone regardless of their ability to throw a baseball, shoot a basket or tackle a wide receiver.

 

Read Article: Trajectory for Athletes

ROY JONES, JR.

Former World Champion & US Olympian Boxer

Are you experiencing ankle or foot issues due to damaged tissue in articular cartilage, Achilles tendon or Plantar Fascia attachment points, or surrounding soft tissue? CryoText™ is the place to begin. Learning how Wharton’s jelly can be used to replace or supplement damaged tissue with new healthy connective tissue. It can be the first step to getting back on track.

TAKE THE FIRST STEP

Learn how Wharton’s jelly for Connective Tissue Supplementation can used.

Regenative Labs’ resources are divided into the following categories:

Discovery icon - magnifying glass

Discover

Discover our catalogue of applications showcasing how Regenative Labs’ proprietary products can be used.

View all Applications
arrow
Study Icon - microscope

STUDY

Study the latest innovations and the variety of options available to medical specialties.

VIEW publications
arrow
Explore icon - DNA and magnifying glass

EXPLORE

Explore the detailed descriptions of our products, their make-up and development through our state-of-the-art process and to identify which products are best suited for your patients’ unique needs.

View Products
arrow

Commitment to Quality and Transparency

Regenative Labs is a leader in the field of regenerative medicine. Our commitment to quality and transparency is demonstrated by collecting data from patient outcomes and analyzing it for statistical significance, ensuring physicians make the most informed decision to facilitate the best possible outcomes for their patients.

From our retrospective data repository, you will witness improvements beginning at the 30-day mark.

DATA

Data Collection Protocol Approved by the Institute of Regenerative and Cellular Medicine (IRB)

 

foot + ankle

improvements in nprs and womac

  • Data ranges chart

Ankle/Feet Data ranges chart

This data is based on a sample of 99 patients with various connective tissue defects of the legs, feet, and ankles from 27 different clinics enrolled in our observational study. There are 61 males and 38 females, aged 36 to 95. Ninety days after the Wharton’s jelly application, patients reported a 32% improvement in NPRS (current pain) and a 29% overall WOMAC improvement (pain/ stiffness/ function).

Published Observational Case Study Following 8 Patients for 90 Days After a Single Application

Tissue Defects Associated with Tarsal Tunnel Syndrome: An Observational Data Collection Study

READ THE CASE SERIES

Our shared goal is to address the root cause of the problem for patients in debilitating situations and partner to offer an effective and minimally-invasive option.

You know the vital role tissue health plays in the overall well-being of patients. Regenative Labs’ mission is to facilitate predictable patient outcomes by offering the highest quality human tissue allografts available.

Contact Us
arrow

Improving Quality of Life

When we experience pain, our body sends a message that something is wrong. Pain is merely a symptom of an underlying injury. Using steroids or opiates alone to address pain caused by injury masks the issue instead of addressing the root cause.

With connective tissue supplementation, medical providers have an opportunity to address the problem at its source by inserting new, viable connective tissue ECM directly to the site of the breakdown, or defect (via syringe). The patient’s body can use the collagenic superstructure from the newly transplanted Wharton’s jelly as building blocks to fill voids or defects in cartilage beds or other soft tissues.

LEARN About Wharton’s Jelly

About Wharton’s Jelly

Wharton’s Jelly (WJ) was initially characterized in 1656 by Thomas Wharton[1]. Advances in regenerative medicine have increased significantly throughout the past decade. Located between the blood vessels of the umbilical cord and the amniotic epithelium, WJ spans the entire length of the umbilical cord, providing protection, cushioning, and structural support [2,3].

READ RESEARCH ARTICLE

Since its initial discovery, there has been significant interest in the use of WJ in regenerative medicine applications[2].

Initial research centered on WJ as a cellular product, dependent on the metabolic activity of living cells to exert its primary function[3]. However, current research demonstrates that WJ exerts an effect independent of any cellular activity[3]. Initially classified as a mucoid connective tissue, we now know that WJ functions as an ideal system to transplant chemokine and growth factors, in addition to providing a biomechanical microarchitecture for collagen extracellular matrix formation in collagen-based defects[4].

Advantages of Wharton’s Jelly

This connective tissue contains high amounts of extracellular matrix components including collagen types I, III, and V, elastin, and fibronectin [1, 2]. Wharton’s jelly mainly provides cushioning and structural support to the umbilical cord but also contains a natural source of long-chain hyaluronic acid and numerous cytokines and growth factors. Studies have described placental tissues to be “immune privileged” as they rarely evoke an immune response in the body, reducing the risk of adverse reactions [4].

STRUCTURAL SUPPORT

Wharton’s jelly provides a natural scaffold to facilitate cellular adhesion [1, 2].

CITATIONS:

1. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton’s jelly derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013 May 31;14(6):11692-712. doi: 10.3390/ijms140611692. PMID: 23727936; PMCID: PMC3709752.

2. Gupta A, El-Amin SF 3rd, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cord derived Wharton’s jelly for regenerative medicine applications. J Orthop Surg Res. 2020 Feb 13;15(1):49. doi: 10.1186/s13018-020-1553-7. PMID: 32054483; PMCID: PMC7017504.

3. Deus IA, Mano JF, CustĂłdio CA. Perinatal tissues and cells in tissue engineering and regenerative medicine. Acta Biomater. 2020 Jul 1;110:1-14. doi: 10.1016/j. actbio.2020.04.035. Epub 2020 May 14. PMID: 32418650.

4. Jadalannagari S, Converse G, McFall C, Buse E, Filla M, Villar MT, Artigues A, MellotAJ, Wang J, Detamore MS, Hopkins RA, Aljitawi OS. Decellularized Wharton’s Jelly from human umbilical cord as a novel 3D scaffolding material for tissue engineering applications. PLoS One. 2017 Feb 21;12(2):e0172098. doi: 10.1371/journal. pone.0172098. Erratum in: PLoS One. 2017 Mar 7;12 (3):e0173827. PMID: 28222169; PMCID: PMC5319682.

CryoText™ Product Information

For more information about our Cryotext product, visit the link below.

Pricing and PLACING AN order

For pricing or to place an order, login or setup an account to get immediate access to our MEDNGINE platform.

DON’t HESITATE TO REACH OUT.

If you have any further questions, please contact us. We look forward to speaking with you!

CODE LIST

Download the ICD-10 Code List to Identify Other Potential Use Sites.

DOWNLOAD HERE